Search ARM

Indapta is a biotechnology company harnessing the natural power of the immune system to fight hematologic and solid cancers with its universal natural killer (NK) cell platform derived from healthy donors. The company’s allogeneic platform is based on a subset of NK cells that are deficient in the FceR1g protein, and are called g-NK cells (g minus NK cells). These cells are particularly potent at killing cancer cells when combined with monoclonal antibodies. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies. Indapta is based in Houston, TX, and Seattle, WA.

Contact Indapta Therapeutics
Visit Website